Publications

2018

  1. Molina CE, Abu-Taha IH, Wang Q, Roselló-Díez E, Kamler M, Nattel S, Ravens U, Wehrens XHT, Hove-Madsen L, Heijman J, Dobrev D (2018) Profibrotic, Electrical, and Calcium-Handling Remodeling of the Atria in Heart Failure Patients With and Without Atrial Fibrillation. Front Physiol. Oct 09, Epub ahead of print. (IF: 3.394) – [Pubmed]
  2. Thomas D, Christ T, Fabritz L, Goette A, Hammwöhner M, Heijman J, Kockskämper J, Linz D, Odening KE, Schweizer PA, Wakili R, Voigt N. (2018) German Cardiac Society Working Group on Cellular Electrophysiology state-of-the-art paper: impact of molecular mechanisms on clinical arrhythmia management Clin Res Cardiol. Oct 10; Epub ahead of print. (IF: 4.455) – [Pubmed]
  3. Sutanto H, Dobrev D, Heijman J (2018) Resveratrol: an effective pharmacological agent to prevent inflammation-induced atrial fibrillation? Naunyn Schmiedebergs Arch Pharmacol. Sep 20; Epub ahead of print. (IF: 2.376) – [Pubmed]
  4. Clerx M, Heijman J, Collins P, Volders PGA (2018) Predicting changes to INa from missense mutations in human SCN5A. Sci Rep. Aug 24;8(1):12797. (IF: 4.122) – [Pubmed]
  5. Sutanto H, van Sloun B, Schönleitner P, van Zandvoort MAMJ, Antoons G, Heijman J (2018) The Subcellular Distribution of Ryanodine Receptors and L-type Ca2+ Channels Modulates Ca2+-transient Properties and Spontaneous Ca2+-release Events in Atrial Cardiomyocytes. Front Physiol. Manuscript accepted on July 23, 2018. (IF: 3.394) – [Pubmed]
  6. Heijman J, Dobrev D, Crijns HJGM (2018) Electrocardiographic characteristics associated with atrial fibrillation – What do they tell us? Int J Cardiol. 266:143-144. (IF: 6.189) – [Pubmed]
  7. Heijman J, Guichard JB, Dobrev D, Nattel S (2018) Translational challenges in atrial fibrillation. Circ Res. 122(5):752-773. (IF: 11.551) – [Pubmed]
  8. Heijman J, Kirchner D, Kunze F, Chrétien EM, Michel-Reher MB, Voigt N, Knaut M, Michel MC, Ravens U, Dobrev D (2018) Muscarinic type-1 receptors contribute to IK,ACh in human atrial cardiomyocytes and are upregulated in patients with chronic atrial fibrillation. Int J Cardiol. 255:61-68. (IF: 6.189) – [Pubmed]
  9. Heijman J, Dobrev D (2018) Ion channels as part of macromolecular multiprotein complexes : Clinical significance. Herzschrittmacherther Elektrophysiol. 29(1):30-35. (IF: -/-) – [Pubmed]
  10. Abu-Taha IH, Heijman J, Feng Y, Vettel C, Dobrev D, Wieland T (2018) Regulation of heterotrimeric G-protein signaling by NDPK/NME proteins and caveolins: an update.
    Lab Invest. 98(2):190-197. (IF: 4.857) – [Pubmed]

2017

  1. Heijman J, Dobrev D (2017) Inhibition of Small-Conductance Ca2+-Activated K+ Channels: The Long-Awaited Breakthrough for Antiarrhythmic Drug Therapy of Atrial Fibrillation? Circ Arrhythm Electrophysiol. 10(10). pii: e005776 (IF: 5.410)- [Pubmed]
  2. Heijman J, Dobrev D, Crijns HJGM (2017) Targeting supraventricular ectopic complexes: Which approach should be used and how does it affect atrial fibrillation? Int J Cardiol. 244:202-203. (IF: 6.189)- [Pubmed]
  3. Heijman J, Ghezelbash S, Dobrev D (2017) Investigational antiarrhythmic agents: promising drugs in early clinical development. Expert Opin Investig Drugs. Epub Jul 10th (IF: 4.030) – [Pubmed]
  4. Tomek J, Rodriguez B, Bub G, Heijman J (2017) β-adrenergic receptor stimulation inhibits proarrhythmic alternans in post-infarction border zone cardiomyocytes: a computational analysis. Am J Physiol Heart Circ Physiol. Epub May 26th (IF: 3.840) – [Pubmed]
  5. Neef S, Heijman J, Otte K, Dewenter M, Saadatmand AR, Meyer-Roxlau S, Antos CL, Backs J, Dobrev D, Wagner M, Maier LS, El-Armouche A (2017) Chronic loss of inhibitor-1 diminishes cardiac RyR2 phosphorylation despite exaggerated CaMKII activity. Naunyn Schmiedebergs Arch Pharmacol. Epub Apr 27th (IF: 2.376) – [Pubmed]
  6. Heijman J, Ghezelbash S, Wehrens XH, Dobrev D (2017) Serine/Threonine Phosphatases in Atrial Fibrillation. J Mol Cell Cardiol, 103:110-120. (IF: 4.874) – [Pubmed]
  7. Schmidt C, Wiedmann F, Zhou XB, Heijman J, Voigt N, Ratte A, Lang S, Kallenberger SM, Campana C, Weymann A, De Simone R, Szabo G, Ruhparwar A, Kallenbach K, Karck M, Ehrlich JR, Baczkó I, Borggrefe M, Ravens U, Dobrev D, Katus HA, Thomas D (2017) Inverse remodelling of K2P3.1 K+ channel expression and action potential duration in left ventricular dysfunction and atrial fibrillation: implications for patient-specific antiarrhythmic drug therapy. Eur Heart J. 38(22): 1764-1774 (IF: 15.064) – [Pubmed]
  8. Abu-Taha IH*, Heijman J*, Hippe HJ, Wolf NM, El-Armouche A, Nikolaev VO, Schäfer M, Würtz CM, Neef S, Voigt N, Baczkó I, Varró A, Müller M, Meder B, Katus HA, Spiger K, Vettel C, Lehmann LH, Backs J, Skolnik EY, Lutz S, Dobrev D#, Wieland T# (2017) Nucleoside Diphosphate Kinase-C Suppresses cAMP Formation in Human Heart Failure. Circulation, 135(9): 881-897. *equally contributing first authors, #co-senior and co-corresponding authors (IF: 17.047) – [Pubmed]
  9. Grandi E, Sanguinetti MC, Bartos DC, Bers DM, Chen-Izu Y, Chiamvimonvat N, Colecraft HM, Delisle BP, Heijman J, Navedo MF, Noskov S, Proenza C, Vandenberg JI, Yarov-Yarovoy V (2017) Potassium channels in the heart: structure, function and regulation. J Physiol, 595(7): 2209-2228. (IF: 4.731) – [Pubmed]
  10. Chiamvimonvat N, Chen-Izu Y, Clancy CE, Deschenes I, Dobrev D, Heijman J, Izu L, Qu Z, Ripplinger CM, Vandenberg JI, Weiss JN, Koren G, Banyasz T, Grandi E, Sanguinetti MC, Bers DM, Nerbonne JM (2017) Potassium currents in the heart: Functional roles in repolarization, arrhythmia and therapeutics. J Physiol, 595(7): 2229-2252. (IF: 4.731) – [Pubmed]

2016

  1. Molina CE*, Heijman J*, Dobrev D (2016) Differences in left versus right ventricular electrophysiological properties in cardiac dysfunction and arrhythmogenesis. Arrhythm Electrophysiol Rev, 5(1): 14-9. *equally contributed first authors (IF: -/-) – [Pubmed]
  2. Heijman J, Dobrev D (2016) Challenges to the translation of basic science findings to atrial fibrillation therapies. Future Cardiol, 12(3): 251-4. (IF: -/-) – [Pubmed]
  3. Heijman J*, Algalarrondo V*, Voigt N, Melka J, Wehrens XH, Dobrev D, Nattel S (2016) The value of basic research insights into atrial fibrillation mechanisms as a guide to therapeutic innovation: a critical analysis. Cardiovasc Res, 109(4): 467-79. *equally contributed first authors (IF: 5.465) – [Pubmed]
  4. Heijman J, Schirmer I, Dobrev D (2016) The multiple proarrhythmic roles of cardiac calcium-handling abnormalities: triggered activity, conduction abnormalities, beat-to-beat variability and adverse remodeling. Europace, 18(10): 1452-1455. (IF: 4.021) – [Pubmed]
  5. Heijman J, Erfanian Abdoust P, Voigt N, Nattel S, Dobrev D (2016) Computational models of atrial cellular electrophysiology and calcium handling, and their role in atrial fibrillation. J Physiol, 594(3): 537-53 (IF: 4.731) – [Pubmed]

2015

  1. Heijman J, Crijns HJGM (2015) T-wave right slope provides a new angle in the prediction of drug-induced ventricular arrhythmias. Cardiovasc Drugs Ther, 29(5):411-413. (IF: 3.189) – [Pubmed]
  2. Voigt N, Heijman J, Dobrev D (2015) New antiarrhythmic targets in atrial fibrillation. Future Cardiol, 11(6):645-54. (IF: -/-) – [Pubmed]
  3. Heijman J, Dobrev D (2015) Irregular Rhythm and Atrial Metabolism Are Key for the Evolution of Proarrhythmic Atrial Remodeling in Atrial Fibrillation. Basic Res Cardiol, 110(4): 41. (IF: 6.008) – [Pubmed]
  4. Schmidt C, Wiedmann F, Voigt N, Zhou XB, Heijman J, Lang S, Albert V, Kallenberger S, Ruhparwar A, Szabó G, Kallenbach K, Karck M, Borggrefe M, Biliczki P, Ehrlich JR, Baczkó I, Lugenbiel P, Schweizer PA, Donner BC, Katus HA, Dobrev D, Thomas D (2015) Upregulation of K2P3.1 K+ Current Causes Action Potential Shortening in Patients with Chronic Atrial Fibrillation Circulation, 132(2): 82-92. (IF: 17.047) – [Pubmed]
  5. Heijman J, Heusch G, Dobrev D (2015) Tools to keep the clock ticking: molecular approaches to treat sinus node dysfunction. Cardiology, 132(1): 45-48. (IF: 1.994) – [Pubmed]
  6. Heijman J*, Voigt N*, Ghezelbash S, Schirmer I, Dobrev D (2015) Calcium handling abnormalities as a target for atrial fibrillation therapeutics: How close to clinical implementation? J Cardiovasc Pharmacol, 66(6):515-22. *equally contributed first authors (IF: 2.462) – [Pubmed]

2014

  1. Heijman J, Dobrev D (2014) Rat engineered heart tissue – a novel tool in the safety pharmacology toolkit? Basic Res Cardiol, 109(6): 437. (IF: 6.008) – [Pubmed]
  2. Spätjens RLHMG, Bébarová M, Seyen SRM, Lentink V, Jongbloed RJ, Arens YHJM, Heijman J, Volders PGA (2014) Long-QT mutation p.K557E Kv7.1: dominant-negative suppression of IKs, but preserved cAMP-dependent upregulation. Cardiovasc Res, 104(1): 216-225. (IF: 5.465) – [Pubmed]
  3. Heijman J, Voigt N, Wehrens XHT, Dobrev D (2014) Calcium dysregulation in atrial fibrillation: the role of CaMKII. Front Pharmacol, 5: 30. (IF: 4.418) – [Pubmed]
  4. Heijman J*, Voigt N*, Nattel S, Dobrev D (2014) Cellular and Molecular Electrophysiology of Atrial Fibrillation Initiation, Maintenance and Progression. Circ Res, 114(9): 1483-1499. *equally contributed first authors (IF: 11.551) – [Pubmed]
  5. Voigt N, Heijman J, Dobrev D (2014) Kardiovaskuläre Pharmakotherapie: Risiken und Nebenwirkungen. Herz, 39(2): 227–24. (IF: 0.751) – [Pubmed]
  6. Heijman J, Voigt N, Carlsson LG, Dobrev D (2014) Cardiac Safety Assays. Curr Opin Pharmacol, 15: 16-21. (IF: 4.769) – [Pubmed]
  7. Voigt N*, Heijman J*, Wang Q, Chiang DY, Li N, Karck M, Wehrens XHT, Nattel S, Dobrev D (2014) Cellular and Molecular Mechanisms of Atrial Arrhythmogenesis in Patients with Paroxysmal Atrial Fibrillation. Circulation, 129(2): 145-156. *equally contributed first authors (IF: 17.047) – [Pubmed]
  8. Voigt N, Abu-Taha I, Heijman J, Dobrev D (2014) Constitutive activity of the acetylcholine-activated potassium current IK,ACh in cardiomyocytes. Adv Pharmacol. 2014;70:393-409 (IF: -/-) – [Pubmed]

2013

  1. Heijman J*, Dewenter M*, El-Armouche A, Dobrev D (2013) Function and regulation of Serine/Threonine phosphatases in the healthy and diseased heart. J Mol Cell Cardiol, 64C:90-98. (IF: 4.874)
  2. Heijman J, Heusch G, Dobrev D (2013) Pleiotropic effects of antiarrhythmic agents: dronedarone in the treatment of atrial fibrillation. Clin Med Insights: Cardiol, 7:127-140. (IF: -/-)
  3. Heijman J, Voigt N, Abu-Taha IH, Dobrev D (2013) Rhythm control of atrial fibrillation in heart failure. Heart Fail Clin, 9(4):407-415. (IF: 1.764)
  4. Heijman J, Zaza A, Johnson DM, Rudy Y, Peeters RLM, Volders PGA, Westra RL (2013) Determinants of beat-to-beat variability of repolarization duration in the canine ventricular myocyte: a computational analysis. PLoS Comput Biol, 9(8):e1003202. (IF: 4.587)
  5. Heijman J, Dobrev D (2013) KCNQ1 autoantibodies: another way to regulate IKs. Cardiovasc Res, 98(3):329-331. (IF: 5.465)
  6. Heijman J, Dobrev D (2013) Pleiotropic actions of amiodarone: still puzzling after half a century. Naunyn Schmiedeberg’s Arch Pharmacol, 386(7):571-574. (IF: 2.376)
  7. Voigt N*, Heijman J*, Trausch A, Mintert-Jancke E, Pott L, Ravens U, Dobrev D (2013) Impaired Na+-dependent regulation of acetylcholine-activated inward-rectifier K+ current modulates action potential rate dependence in patients with chronic atrial fibrillation. J Mol Cell Cardiol, 53(3):142-152. (IF: 4.874)
  8. Tsuji Y*, Heijman J*, Nattel S, Dobrev D (2013) Electrical storm: recent pathophysiological insights and therapeutic consequences. Basic Res Cardiol, 108(2): 336-345. (IF: 6.008)
  9. Johnson DM*, Heijman J*, Bode EF, Greensmith DJ, Van der Linde H, Abi-Gerges N, Eisner D, Trafford AW, Volders PGA (2013) Diastolic spontaneous calcium release from the sarcoplasmic reticulum increases beat-to-beat variability of repolarization in canine ventricular myocytes after β-adrenergic stimulation. Circ Res, 112(2):246-256. (IF: 11.551)
  10. Heijman J, Wehrens XHT, Dobrev D (2013) Atrial arrhythmogenesis in catecholaminergic polymorphic ventricular tachycardia – is there a mechanistic link between sarcoplasmic reticulum Ca2+ leak and reentry? Acta Physiol (Oxf.), 207(2):208-211. (IF: 4.066)
  11. Heijman J, Voigt N, Dobrev D (2013) New directions in antiarrhythmic drug therapy for atrial fibrillation. Future Cardiol, 9(1):71-88. (IF: -/-)